- A 60-year-old female with a 0.9 cm invasive ductal carcinoma, ER 70%, PR 30%, HER2 3+ by immunohistochemistry, grade 2, with 0/3 sentinel lymph nodes involved with tumor
- The APT trial showed a 3-year rate of survival free from invasive disease of 98.7% for node negative tumors up to 3 cm in size with use of weekly paclitaxel / trastuzumab
1. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med. 2015;372(2):134-141.
2. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2019;37(22):1868-1875.